Christopher Ryan Sullivan is CFO at Avalo Therapeutics, Inc. (AVTX). They have made 4 open-market trades across 2 companies since 2020, most recently 2026-09-16.
CIK 0001810417
4 open-market purchases totalling $22K since 2020, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AVTX | SELL · 10b5-1 | 2026-09-16 | 2026-09-18 | $16.33 | $202K | -8.6% | — | — |
| AVTX | SELL · 10b5-1 | 2026-09-10 | 2026-09-11 | $17.62 | $179K | -5.5% | -18.3% | — |
| AVTX | SELL · 10b5-1 | 2026-08-17 | 2026-08-19 | $19.94 | $1.5M | -5.3% | -18.5% | — |
| AVTX | SELL · 10b5-1 | 2026-05-07 | 2026-05-11 | $24.12 | $449K | -17.0% | -34.7% | -1.4% |
| AVTX | SELL · 10b5-1 | 2026-05-06 | 2026-05-07 | $20.19 | $949K | -28.5% | -44.1% | -17.1% |
| AVTX | SELL · 10b5-1 | 2026-04-29 | 2026-05-01 | $13.16 | $223K | +42.8% | +13.5% | +39.7% |
| AVTX | SELL · 10b5-1 | 2026-04-01 | 2026-04-03 | $16.96 | $271K | -26.3% | -23.9% | +4.2% |
| AVTX | BUY | 2023-06-09 | 2023-06-13 | $3.42 | $2K | -86.3% | -90.7% | -97.7% |
| AVTX | BUY | 2021-12-10 | 2021-12-14 | $1.57 | $1K | +1.1% | -44.9% | -63.2% |
| CERC | BUY | 2020-12-10 | 2020-12-14 | $2.28 | $12K | -0.4% | -0.7% | +21.0% |
| CERC | BUY | 2020-06-10 | 2020-06-11 | $2.28 | $7K | -6.2% | -10.2% | -6.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.